European Journal of Cancer
Volume 41, Issue 17 , Pages 2673-2681 , November 2005

Vaginal oestrogen therapy after breast cancer: Is it safe?

Received 7 February 2005 ,Revised 26 July 2005 ,Accepted 28 July 2005.

References 

  1. Parkina DM, Braya FY, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer. 2001;37:S4–S66
  2. Jemal A, Tiwari RC, Murray T, et al. Cancer Statistics, 2004. CA Cancer J Clin. 2004;54:8–29
  3. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–1717
  4. The Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst. 2002;94:606–616
  5. Hankinson SE, Willett WC, Manson JE, et al. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 1998;90:1292–1299
  6. Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. Lancet Oncol. 2001;2:133–140
  7. Chlebowski RT, Hendrix SL, Langer RD, et al. for the WHI investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative Randomized Trial. JAMA. 2003;289:3243–3253
  8. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet. 1997;350:1047–1059
  9. Cuzick J. Is hormone replacement therapy safe for breast cancer patients?. J Natl Cancer Inst. 2001;93:733–734
  10. Gambrell RD. Role of progestogens in the prevention of breast cancer. Maturitas. 1986;8:169–176
  11. Santen RJ. Risk of breast cancer with progestins: critical assessment of current data. Steroids. 2003;68:953–964
  12. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomised controlled trial. JAMA. 2004;291:1701–1712
  13. Stockwell S. Classics in oncology. George Thomas Beatson, M.D. (1848–1933). CA Cancer J Clin. 1983;33:105–121
  14. Jensen EV, Jordan VC. The estrogen receptor: a model for molecular medicine. Clin Cancer Res. 2003;9:1980–1989
  15. Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351:1451–1467
  16. Muss HB. Endocrine therapy for advanced breast cancer: a review. Breast Cancer Res Treat. 1992;21:15–26
  17. Kroman N, Mouridsen HT. Prognostic influence of pregnancy before, around, and after diagnosis of breast cancer. The Breast. 2003;12:516–521
  18. Gelber S, Coates AS, Goldhirsch A, et al. Effect of pregnancy on overall survival after the diagnosis of early-stage breast cancer. J Clin Oncol. 2001;19:1671–1675
  19. Blakely LJ, Buzdar AU, Lozada JA, et al. Effects of pregnancy after treatment for breast carcinoma on survival and risk of recurrence. Cancer. 2004;100:465–469
  20. Crandall C, Petersen L, Ganz PA, et al. Association of breast cancer and its therapy with menopause-related symptoms. Menopause. 2004;11:519–530
  21. Biglia N, Cozzarella M, Cacciari F, et al. Menopause after breast cancer: a survey on breast cancers survivors. Maturitas. 2003;45:29–38
  22. Pritchard KI. The role of hormone replacement therapy in women with a previous diagnosis of breast cancer and a review of possible alternatives. Ann Oncol. 2001;12:301–310
  23. The Hormone Foundation, Canadian Breast Cancer Research Initiative, National Cancer Institute of Canada, Endocrine Society, and the University of Virginia Cancer Center and Woman’s Place. Treatment of estrogen deficiency symptoms in women surviving breast cancer. J Clin Endocrinol Metab. 1998;83:1993–2000
  24. Col NF, Hirota LK, Orr RK, et al. Hormone replacement therapy after breast cancer: a systematic review and quantitative assessment of risk. J Clin Oncol. 2001;19:2357–2363
  25. O’Meara ES, Rossing MA, Daling JR, et al. Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. J Natl Cancer Inst. 2001;93:754–762
  26. Decker DA, Pettinga JE, VanderVelde N, et al. Estrogen replacement therapy in breast cancer survivors: a matched-controlled series. Menopause. 2003;10:277–285
  27. Biglia N, Gadducci A, Ponzone R, et al. Hormone replacement therapy in cancer survivors. Maturitas. 2004;48:333–346
  28. Holmberg L, Anderson H For the HABITS steering and data monitoring committees. HABITS (hormonal replacement therapy after breast cancer – is it safe?), a randomised comparison: trial stopped. Lancet. 2004;363:453–455
  29. North American Menopause Society. Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society. Menopause. 2004;11:11–33
  30. The editor. HABITS (Hormonal Replacement Therapy After Breast Cancer-Is It Safe?): a randomized comparison trial stopped. Obstet Gynecol Survey 2004, 59, 442–443.
  31. Loprinzi CL, Abu-Ghazaleh S, Sloan JA, et al. Phase III randomised double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer. J Clin Oncol. 1997;15:969–973
  32. Laan E, van Lunsen RHW. Hormones and sexuality in postmenopausal women: a psychophysiological study. J Psichosom Obstet Gynaecol. 1997;18:126–133
  33. Cardozo L, Bachmann G, McClish D, et al. Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: Second, report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol. 1998;92:722–727
  34. Rigg LA, Hermann H, Yen SC. Absorption of estrogens from vaginal creams. N Engl J Med. 1978;298:195–197
  35. Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. The Cochrane Database of Systematic Reviews volume 2004, 4, CD001500.
  36. Vooijs GP, Geurts TBP. Review of the endometrial safety during intravaginal treatment with estriol. Eur J Obstet Gynecol Reprod Biol. 1995;62:101–106
  37. Weiderpass E, Baron JA, Adami HO, et al. Low-potency oestrogen and risk of endometrial cancer: a case-control study. Lancet. 1999;353:1824–1828
  38. Ganz PA, Desmond KA, Belin TR, et al. Predictors of sexual health in women after a breast cancer diagnosis. J Clin Oncol. 1999;17:2371–2380
  39. Dowsett M, Folkerd E. Deficits in plasma oestradiol measurement in studies and management of breast cancer. Breast Cancer Res. 2005;7:1–4
  40. Nilsson K, Heimerb G. Low-dose 17P-oestradiol during maintenance therapy – a pharmacokinetic and pharmacodynamic study. Maturitas. 1995;21:33–38
  41. Heimer GM, Englund DE. Estriol absorption after long-term vaginal treatment and gastrointestinal absorption as influenced by a meal. Acta Obstet Gynecol Scand. 1984;63:563–567
  42. Santen RJ, Pinkerton JV, Conaway M, et al. Treatment of urogenital atrophy with low-dose estradiol: preliminary results. Menopause. 2002;9:179–187
  43. Simunic V, Banovic I, Ciglar S, et al. Local estrogen treatment in patients with urogenital symptoms. Int J Gynaecol Obstet. 2003;82:187–197
  44. Collins JA, Schlesselman JJ. Hormone replacement therapy and endometrial cancer. In:  Lobo RA editors. Treatment of the postmenopausal woman. Philadelphia (PA)/Baltimore (MD): Lippincott/Williams & Wilkins; 1999;p. 503–512
  45. Dew JE, Wren BG, Eden JA. A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer. Climateric. 2003;6:45–52
  46. Baker VL. Alternatives to oral estrogen replacement: transdermal patches, percutaneous gels, vaginal creams and rings, implants, and other methods of delivery. Obstet Gynecol Clin North Am. 1994;21:271–297
  47. Henriksson L, Stjernquist M, Boquist L. A one-year multicenter study of efficacy and safety of a continuous, low-dose, estradiol releasing vaginal ring (estring) in postmenopausal women with symptoms and signs of urogenital aging. Am J Obstet Gynecol. 1996;174:85–92
  48. Notelovitz M, Funk S, Nanavati N, et al. Estradiol absorption from vaginal tablets in postmenopausal women. Obstet Gynecol. 2002;99:556–562
  49. Dugal R, Hesla K, Sordal T, et al. Comparison of usefulness of estradiol vaginal tablets and estriol vagitories for treatment of vaginal atrophy. Acta Obstet Gynecol Scand. 2000;79:293–297
  50. Naessen T, Rodriguez-Macias K. Endometrial thickness and uterine diameter not affected by ultralow doses of 17β-estradiol in elderly women. Am J Obstet Gynecol. 2002;186:944–947
  51. Mettler L, Olsen PG. Long term treatment of atrophic vaginitis with low-dose oestradiol vaginal tablets. Maturitas. 1991;14:23–31
  52. Nash HA, Bracheb V, Alvarez-Sanchezb F, et al. Estradiol delivery by vaginal rings: potential for hormone replacement therapy. Maturitas. 1997;26:27–33
  53. Head KA. Estriol: safety and efficacy. Alt Med Rev. 1998;3:101–113
  54. Bottiglione F, Volpe A, Esposito G, et al. Transvaginal estriol administration in postmenopausal women: a double blind comparative study of two different doses. Maturitas. 1995;22:227–232
  55. Toniolo P, Lukanova A. The challenge of measuring circulating estradiol at low concentrations. Breast Cancer Res. 2005;7:45–47

PII: S0959-8049(05)00724-0

doi: 10.1016/j.ejca.2005.07.015

European Journal of Cancer
Volume 41, Issue 17 , Pages 2673-2681 , November 2005

Article Tools

* Image Usage & Resolution